Research

The MELISSA project develops an AI-powered platform to enhance insulin therapy for diabetes patients through personalized treatment solutions. Given the complexities of insulin management, MELISSA’s approach aims to reduce the daily burden on patients while significantly advancing the quality and precision of care.

MELISSA’s research framework involves the integration of preclinically validated AI-driven tools into a comprehensive digital platform, all within stringent ethical guidelines. Key to this research is a clinical study across Denmark, Germany, Greece, and the Netherlands, where real-world data from insulin-treated patients will assess the platform’s effectiveness and usability. A thorough cost-benefit analysis will further explore the economic viability of the MELISSA platform.

Ultimately, MELISSA seeks to provide a safe and evidence-based clinical decision support systems for affordable treatment for everyone with diabetes requiring insulin treatment. Health care providers will be able to better predict patients’ responses to the individually tailored treatment. They can also rely on improved clinical guidelines thanks to the novel, clinically validated and (cost-) effective AI solutions. As such, MELISSA will be the first AI-powered solution to go through regulatory approval for clinical investigation in several European countries.